0 2 V3 v3 NN 3 7 loop loop NN 8 10 of of IN 11 16 human human JJ 17 33 immunodeficiency immunodeficiency NN 34 39 virus virus NN 40 44 type type NN 45 46 1 1 CD 47 57 suppresses suppress VBZ 58 69 interleukin interleukin NN 70 79 2-induced 2-induced JJ 80 81 T t NN 82 86 cell cell NN 87 93 growth growth NN 94 95 [ [ ( 95 104 published publish VBN 105 112 erratum erratum NN 113 120 appears appear VBZ 121 123 in in IN 124 128 AIDS AIDS NNP 129 132 Res Res NNP 133 136 Hum Hum NNP 137 149 Retroviruses Retroviruses NNP 150 154 1997 1997 CD 155 158 May May NNP 159 170 1;13(7):633 1;13(7):633 CD 170 171 ] ] ) 173 175 We we PRP 176 182 tested test VBD 183 186 the the DT 187 193 effect effect NN 194 196 of of IN 197 202 three three CD 203 209 linear linear JJ 210 212 or or CC 213 216 two two CD 217 221 loop loop NN 222 230 peptides peptide NNS 231 238 derived derive VBN 239 243 from from IN 244 247 the the DT 248 250 V3 v3 NN 251 257 region region NN 258 260 of of IN 261 264 the the DT 265 273 HTLV-III HTLV-III NNP 274 278 BH10 BH10 NNP 279 284 clone clone NN 285 287 or or CC 288 291 the the DT 292 295 SF2 sf2 NN 296 302 strain strain NN 303 305 of of IN 306 311 human human JJ 312 328 immunodeficiency immunodeficiency NN 329 334 virus virus NN 335 339 type type NN 340 341 1 1 CD 342 344 on on IN 345 356 IL-2-driven il-2-driven JJ 357 358 T t NN 359 363 cell cell NN 364 377 proliferation proliferation NN 377 378 . . . 379 386 V3-BH10 V3-BH10 NNP 386 387 , , , 388 393 which which WDT 394 402 consists consist VBZ 403 405 of of IN 406 408 42 42 CD 409 414 amino amino NN 415 420 acids acid NNS 421 424 and and CC 425 428 has have VBZ 429 430 a a DT 431 435 loop loop NN 436 445 structure structure NN 445 446 , , , 447 457 suppressed suppress VBD 458 469 IL-2-driven il-2-driven JJ 470 483 proliferation proliferation NN 484 486 of of IN 487 490 all all DT 491 505 IL-2-dependent il-2-dependent JJ 506 511 cells cell NNS 512 513 [ [ ( 513 519 Kit225 kit225 NN 519 520 , , , 521 532 ED-40515(+) ED-40515(+) NNP 532 533 , , , 534 538 KT-3 KT-3 NNP 538 539 , , , 540 545 7-day 7-day JJ 546 556 PHA-blasts pha-blast NNS 556 557 , , , 558 561 and and CC 562 567 fresh fresh JJ 568 578 peripheral peripheral JJ 579 584 blood blood NN 585 596 mononuclear mononuclear JJ 597 602 cells cell NNS 602 603 ] ] ) 604 610 tested test VBN 610 611 , , , 612 619 whereas whereas IN 620 622 it it PRP 623 626 did do VBD 627 630 not not RB 631 639 suppress suppress VB 640 643 the the DT 644 648 cell cell NN 649 655 growth growth NN 656 658 of of IN 659 675 IL-2-independent il-2-independent JJ 676 680 cell cell NN 681 686 lines line NNS 687 688 ( ( ( 688 694 Hut102 Hut102 NNP 694 695 , , , 696 702 Molt-4 molt-4 NN 702 703 , , , 704 707 and and CC 708 714 Jurkat Jurkat NNP 714 715 ) ) ) 715 716 . . . 717 721 This this DT 722 733 suppressive suppressive JJ 734 740 effect effect NN 741 744 was be VBD 745 749 also also RB 750 754 seen see VBN 755 757 in in IN 758 769 IL-2-driven il-2-driven JJ 770 774 cell cell NN 775 781 growth growth NN 782 784 of of IN 785 797 CD8-positive cd8-positive JJ 798 809 lymphocytes lymphocyte NNS 810 818 purified purify VBN 819 823 from from IN 824 829 7-day 7-day JJ 830 840 PHA-blasts pha-blast NNS 840 841 , , , 842 852 indicating indicate VBG 853 857 that that IN 858 861 CD4 cd4 NN 862 871 molecules molecule NNS 872 876 were be VBD 877 880 not not RB 881 889 required require VBN 890 893 for for IN 894 897 the the DT 898 909 suppression suppression NN 909 910 . . . 911 914 The the DT 915 924 treatment treatment NN 925 929 with with IN 930 937 anti-V3 anti-v3 JJ 938 942 loop loop NN 943 953 monoclonal monoclonal JJ 954 962 antibody antibody NN 963 964 ( ( ( 964 967 902 902 CD 968 976 antibody antibody NN 976 977 ) ) ) 978 988 completely completely RB 989 998 abolished abolish VBD 999 1002 the the DT 1003 1014 suppressive suppressive JJ 1015 1021 effect effect NN 1022 1024 of of IN 1025 1032 V3-BH10 V3-BH10 NNP 1032 1033 . . . 1034 1036 In in IN 1037 1045 addition addition NN 1045 1046 , , , 1047 1054 V3-BH10 V3-BH10 NNP 1055 1064 generated generate VBD 1065 1068 the the DT 1069 1075 arrest arrest NN 1076 1078 of of IN 1079 1085 Kit225 kit225 NN 1086 1091 cells cell NNS 1092 1095 and and CC 1096 1100 also also RB 1101 1109 purified purify VBN 1110 1122 CD8-positive cd8-positive JJ 1123 1134 lymphocytes lymphocyte NNS 1135 1137 in in IN 1138 1140 G1 g1 NN 1141 1146 phase phase NN 1147 1149 in in IN 1150 1153 the the DT 1154 1162 presence presence NN 1163 1165 of of IN 1166 1170 IL-2 il-2 NN 1170 1171 . . . 1172 1179 Neither neither CC 1180 1189 chromatin chromatin NN 1190 1202 condensation condensation NN 1203 1206 nor nor CC 1207 1210 DNA dna NN 1211 1224 fragmentation fragmentation NN 1225 1228 was be VBD 1229 1237 detected detect VBN 1238 1240 in in IN 1241 1247 Kit225 kit225 NN 1248 1253 cells cell NNS 1254 1262 cultured culture VBN 1263 1267 with with IN 1268 1275 V3-BH10 V3-BH10 NNP 1276 1279 and and CC 1280 1284 IL-2 il-2 NN 1284 1285 . . . 1286 1293 V3-BH10 V3-BH10 NNP 1294 1301 neither neither CC 1302 1309 blocked block VBD 1310 1322 radiolabeled radiolabele VBN 1323 1327 IL-2 il-2 NN 1328 1335 binding bind VBG 1336 1338 to to TO 1339 1343 IL-2 il-2 NN 1344 1353 receptors receptor NNS 1354 1357 nor nor CC 1358 1366 affected affect VBN 1367 1374 tyrosyl tyrosyl NN 1375 1390 phosphorylation phosphorylation NN 1391 1393 of of IN 1394 1401 several several JJ 1402 1410 cellular cellular JJ 1411 1419 proteins protein NNS 1420 1421 ( ( ( 1421 1425 p120 p120 NN 1425 1426 , , , 1427 1430 p98 p98 NN 1430 1431 , , , 1432 1435 p96 p96 NN 1435 1436 , , , 1437 1440 p54 p54 NN 1440 1441 , , , 1442 1445 and and CC 1446 1449 p38 p38 NN 1449 1450 ) ) ) 1450 1451 , , , 1452 1457 which which WDT 1458 1460 is be VBZ 1461 1472 immediately immediately RB 1473 1480 induced induce VBN 1481 1483 by by IN 1484 1488 IL-2 il-2 NN 1489 1500 stimulation stimulation NN 1500 1501 . . . 1502 1509 However however RB 1509 1510 , , , 1511 1518 V3-BH10 V3-BH10 NNP 1519 1527 enhanced enhance VBD 1528 1540 IL-2-induced il-2-induced JJ 1541 1545 mRNA mrna NN 1546 1556 expression expression NN 1557 1559 of of IN 1560 1565 c-fos c-fos NN 1566 1569 but but CC 1570 1573 not not RB 1574 1579 c-myc c-myc NN 1580 1582 or or CC 1583 1587 junB junb NN 1587 1588 . . . 1589 1593 Thus thus RB 1593 1594 , , , 1595 1598 the the DT 1599 1606 binding binding NN 1607 1609 of of IN 1610 1612 V3 v3 NN 1613 1617 loop loop NN 1618 1620 of of IN 1621 1626 gp120 gp120 NN 1627 1629 to to TO 1630 1633 the the DT 1634 1638 cell cell NN 1639 1646 surface surface NN 1647 1658 molecule(s) molecule(s) NN 1659 1666 appears appear VBZ 1667 1669 to to TO 1670 1676 affect affect VB 1677 1690 intracellular intracellular JJ 1691 1695 IL-2 il-2 NN 1696 1705 signaling signaling NN 1705 1706 , , , 1707 1712 which which WDT 1713 1718 leads lead VBZ 1719 1721 to to TO 1722 1725 the the DT 1726 1737 suppression suppression NN 1738 1740 of of IN 1741 1753 IL-2-induced il-2-induced JJ 1754 1755 T t NN 1756 1760 cell cell NN 1761 1767 growth growth NN 1767 1768 . . .